We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Bio-Rad and Axis-Shield Sign Agreement for Anti-CCP

By HospiMedica staff writers
Posted on 26 Jan 2007
Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA), a manufacturer and distributor of life science research and clinical diagnostics products and Axis-Shield (Dundee, Scotland), an in vitro diagnostics company, have signed an agreement that gives Bio-Rad access to Axis-Shield's test for the early detection of rheumatoid arthritis (RA).

The new assay will run on Bio-Rad's BioPlex 2200 system and tests for anti-CCP (anti-cyclic citrullinated peptide antibodies). The anti-CCP assay is a significant recent development in the early diagnosis of rheumatoid arthritis, facilitating improved management of this widespread and debilitating condition. The anti-CCP assay is regarded by many experts as the most significant recent development in the early diagnosis of RA, facilitating improved management of this widespread and debilitating condition, affecting over 2 million people in the United States alone.

Svein Lien, Axis-Shield's CEO, commented: "We are very pleased that our important patented assay for anti-CCP will be added to the menu of this versatile platform. We have a history of successful collaboration with Bio-Rad, which is a highly respected and pioneering organization in life sciences and a major player in human diagnostic testing, and believe the BioPlex system will add an extra dimension to anti-CCP marketing.”

"The ability to develop and launch an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system,” said John Goetz, Bio-Rad vice president and group manager of Clinical Diagnostics. "As the first and only fully automated and random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multimarker autoimmune testing that includes rheumatoid arthritis.”

Axis-Shield is a global manufacturer of in vitro diagnostic kits with a focus on new markers in cardiovascular, rheumatoid, infectious, and alcohol-related diseases, diabetes, dementia, and near-patient testing to facilitate improved patient management.

Bio-Rad Laboratories manufactures and distributes a broad range of products for the life science research and clinical diagnostics markets.



Related Links:
Bio-Rad Laboratories
Axis-Shield

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Autoclave
Advance
Infrared Digital Thermometer
R1B1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.